Roth Capital reiterated their buy rating on shares of ContraVir Pharmaceuticals (NYSE:HEPA) in a report published on Thursday, Zacks.com reports.
NYSE HEPA traded up $0.18 during trading hours on Thursday, hitting $3.26. The company’s stock had a trading volume of 131,974 shares.
ContraVir Pharmaceuticals (NYSE:HEPA) last posted its earnings results on Wednesday, August 14th. The company reported ($7.48) EPS for the quarter.
Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B.
Featured Article: Certificate of Deposit (CD)
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.